Early Clinical:
Phase I-IIa

Fortrea has more than 250 team members fully dedicated to early phase studies.

Your clinical pharmacology team brings over 30 years of direct drug development experience.

Optimize your early phase studies with 300+ investigator sites across the globe.

An experienced partner to help you navigate your first-in-human studies.

We offer you a deep, experienced team focused on this crucial phase of molecule development. Let us partner with you as you transition into the clinic with an eye toward future phases.

You only need access to the resources that matter most to your study, and you shouldn’t have to deal with a bigger footprint than you need. We understand. That’s why we deliver the right combination of strategy and execution, resources, and tools that help you meet your end goals. An experienced partner gets you results as you introduce your compound in humans and move to proof-of-concept.

Avoid early clinical missteps.

We help you avoid the study delays and missed recruitment timelines that are far too common, so your focus can be directed on quality, time and cost. By partnering with Fortrea, you can rest assured that your study will stay on track toward the next development milestone. Our processes are specifically designed for early clinical studies. In fact, we have locked more than 1,000 databases and have met our healthy volunteer and patient enrollments over 90% in the past five years.

Deep therapeutic experience matters in clinical design.

You want a team of experts that has a proven track record in your therapeutic area. We deliver recognized thought leaders in early clinical design and execution for a variety of therapeutic indications, including oncology, metabolic, neuroscience, cardiovascular, inflammation and infectious disease.

Stay up to date:
Subscribe for Fortrea news & announcements.